TITLE

A preliminary study of imiquimod treatment in variants of basal cell carcinoma

AUTHOR(S)
McCutcheon, Brion; White, Kenneth; Kotwall, Cyrus; Germolic, Dori; Rebolloso, Yvette; Hamann, Mary Sue; Stiles, Anquonette
PUB. DATE
August 2005
SOURCE
American Surgeon;Aug2005, Vol. 71 Issue 8, p662
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Imiquimod is a topical immune response modifier that has proved efficacious in the treatment of the superficial variant of basal cell carcinoma. The nodular variant of basal cell carcinoma has shown moderate response to imiquimod; other variants have not been tested. The mechanism of action is largely unknown; however, studies indicate the mechanism involves alteration of local cytokine production. The objective of this study is to evaluate the cytokine response of imiquimod in all variants of basal cell carcinoma. Ten patients were selected who had clinically and histologically proven basal cell carcinoma. All lesions were treated with imiquimod once a day, 5 days a week, for 3 weeks. After a 3-week rest period, the lesions were rebiopsied. All biopsy specimens were analyzed via polymerase chain reaction (PCR) for various cytokines. Nine of 10 lesions resolved clinically, which included nodular, superficial, infiltrative, adenoid, and micronodular variants. The cytokine with the greatest change pre- and post-treatment was IL-8, which decreased an average of 44 per cent (P = 0.06). We concluded that topical 5 per cent imiquimod is an effective treatment of various subtypes of basal cell carcinoma. IL-8, which plays an important role in the development and metastasis of melanoma, may be involved in the mechanism of action of imiquimod on cutaneous malignancies. Larger studies are needed to prove the efficacy of imiquimod on nonsuperficial variants of basal cell carcinoma and cutaneous melanoma metastasis.
ACCESSION #
18148299

 

Related Articles

  • Nonhealing painless ulcer on the sole.  // Clinical Advisor;Dec2009, Vol. 12 Issue 12, p47 

    The article presents a case study of a 49 year-old Hispanic man who have an enlarging painless ulcer on the plantar surface of his right foot for three years. He claimed that the ulcer began as a small fleshy bump that had opened and burst and has grown continuously. The lesion drained clear...

  • Saving their skin--and their lives. Oglethorpe, Alice // Good Housekeeping;Jul2005, Vol. 241 Issue 1, p64 

    Shares the experiences of two women in saving their skin and their lives. Cause of the basal cell carcinoma of Toni Anderson of Kansas; Attitude of Amy Cawvey of Hawaii towards her melanoma.

  • Nonmelanoma skin cancer on the rise `down under.' Zabel, Karen // Dermatology Times;Sep97, Vol. 18 Issue 9, p25 

    Reports that the number of people with nonmelanoma skin cancers is on the rise in Australia. Estimated melanoma cases based on a national survey completed in 1996; Comparison of data with United States for 1997 and the deaths that results from the cancer; Site distribution for basal cell...

  • Nonmelanoma Skin Cancer. Samarasinghe, Venura; Madan, Vishal // Journal of Cutaneous & Aesthetic Surgery;Jan2012, Vol. 5 Issue 1, p3 

    Nonmelanoma skin cancer (NMSC) represents the most common form of cancer in Caucasians, with continuing increase in incidence worldwide. Basal cell carcinoma (BCC) accounts for 75% of cases of NMSC, and squamous cell carcinoma (SCC) accounts for the remaining majority of NMSC cases. Whilst...

  • Epidermal Malignant Tumors: Pathogenesis, Influence of UV Light and Apoptosis. Massari, Larisa Prpić; Kaštelan, Marija; Gruber, Franjo // Collegium Antropologicum;2007 Supplement 1, Vol. 31 Issue s1, p83 

    Basal cell carcinoma and squamous cell carcinoma, collectively termed non-melanoma skin cancers are the most commonmalignant tumors in humans. Basal cell carcinoma grows slowly and metastatic spread is very rare. Squamous cell carcinoma is characterized by infiltrative, destructive growth and...

  • Clinical trial indicates role for imiquimod as cancer therapy. Guttman, Cheryl // Dermatology Times;Jun2001, Vol. 22 Issue 6, p52 

    Focuses on the potential of imiquimod, a topical immune response modifier for medical therapy for various skin cancers and precancerous lesions. Cure of superficial basal cell carcinoma on the trunks and extremities; Scope of immunologic activities; Results of successful clinical trial in...

  • Imiquimod in Basal Cell Carcinoma: A Viewpoint by Nathalie Zeitouni. Zeitouni, Nathalie // American Journal of Clinical Dermatology;2005, Vol. 6 Issue 3, p202 

    Considers the use of topical immune response modifier imiquimod for basal cell carcinoma (BCC). Benefit of using alternative immunotherapy approaches to people with BCC; Trails supporting the use of imiquimod for superficial BCC.

  • Imiquimod: A Viewpoint by Stephen Shumack. Shumack, Stephen // American Journal of Clinical Dermatology;2005, Vol. 6 Issue 3, p201 

    Considers the use of topical immune response modifier imiquimod for basal cell carcinoma (BCC). Response of other skin malignacies to immune response modification therapy; Effect of immune response modifiers on the body's immune system.

  • Questioning imiquimod's impact on scars. Kapes, Beth // Dermatology Times;Oct2004, Vol. 25 Issue 10, p48 

    The article evaluates the impact of imiquimod on scars. Best known as the modern-day defender against basal cell carcinoma and actinic keratoses, imiquimod cream (Aldara) is also gaining a reputation for its biosynthetic and clinical results in the treatment of scars and evidence continues to...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics